{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:54:28Z","timestamp":1788609268312,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.ophtha.2016.04.028","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T20:32:07Z","timestamp":1464467527000},"page":"1845-1855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":188,"title":["Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy"],"prefix":"10.1016","volume":"123","clinical-trial-number":[{"clinical-trial-number":"nct00622726","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Helen A.","family":"Mintz-Hittner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"Geloneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Z.","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2016.04.028_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"10.1016\/j.ophtha.2016.04.028_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results","volume":"106","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0002-9394(14)77719-0","article-title":"Ocular neovascularization. The Krill Memorial Lecture","volume":"85","author":"Henkind","year":"1978","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0161-6420(80)35224-X","article-title":"The demonstration of angiogenic activity from ocular tissues. Preliminary report","volume":"87","author":"Glaser","year":"1980","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.028_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/309793a0","article-title":"Vitamin E protects against retinopathy of prematurity through action on spindle cells","volume":"309","author":"Kretzer","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.ophtha.2016.04.028_bib7","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ophtha.2016.04.028_bib8","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.04.028_bib9","first-page":"345","article-title":"Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity","volume":"14","author":"Geisen","year":"2008","journal-title":"Mol Vis"},{"key":"10.1016\/j.ophtha.2016.04.028_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1167\/iovs.13-13429","article-title":"Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity","volume":"55","author":"Wang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.04.028_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0301-4738.29505","article-title":"Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity","volume":"55","author":"Shah","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity: preliminary results of the BEAT-ROP clinical trial","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.04.028_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/archophthalmol.2010.360","article-title":"Visual field extent at 6 years of age in children who had high-risk prethreshold retinopathy of prematurity","volume":"129","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib14","first-page":"124","article-title":"Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings at 4 to 6 years of age","volume":"17","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2013","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2016.04.028_bib15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0161-6420(79)35437-9","article-title":"Anterior segment abnormalities in cicatricial retinopathy of prematurity","volume":"86","author":"Hittner","year":"1979","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.028_bib16","first-page":"17","article-title":"Case series of angle-closure glaucoma after laser treatment for retinopathy of prematurity","volume":"9","author":"Trigler","year":"2005","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2016.04.028_bib17","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","article-title":"Intravitreal bevacizumab for retinopathy of prematurity: refractive error results","volume":"155","author":"Harder","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib19","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/eye.2014.172","article-title":"Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes","volume":"28","author":"Chen","year":"2014","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2016.04.028_bib20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.028_bib21","first-page":"2","article-title":"Bevacizumab as monotherapy for retinopathy of prematurity","volume":"14","author":"Mintz-Hittner","year":"2010","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2016.04.028_bib22","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0161-6420(94)31301-7","article-title":"Postnatal retinal vascularization in former preterm infants with retinopathy of prematurity","volume":"101","author":"Mintz-Hittner","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.028_bib24","first-page":"234","article-title":"Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children","volume":"16","author":"Blair","year":"2012","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2016.04.028_bib25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","author":"The Committee for the Classification of Retinopathy of Prematurity","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib26","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/archopht.124.11.1669-c","article-title":"Standard image of plus disease in retinopathy of prematurity","volume":"124","author":"Capone","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib27","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/eye.2012.111","article-title":"Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity","volume":"26","author":"Lee","year":"2012","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2016.04.028_bib28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/archophthalmol.2011.1802","article-title":"Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity","volume":"130","author":"Patel","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib29","first-page":"457","article-title":"Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity","volume":"14","author":"Jang","year":"2010","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2016.04.028_bib30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/eye.2009.156","article-title":"Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity","volume":"24","author":"Zepeda-Romero","year":"2010","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2016.04.028_bib31","first-page":"323","article-title":"Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab","volume":"17","author":"Ittiara","year":"2014","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2016.04.028_bib32","first-page":"402","article-title":"Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser","volume":"18","author":"Chen","year":"2014","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2016.04.028_bib33","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib34","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ajo.2008.10.006","article-title":"Late recurrence of retinal detachment following successful vitreous surgery for stages 4B and 5 retinopathy of prematurity","volume":"147","author":"Kondo","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib35","article-title":"Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity","volume":"47","author":"Suk","year":"2010","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.ophtha.2016.04.028_bib36","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","article-title":"Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy: 27 month follow-up results from Turkey","volume":"253","author":"Yetik","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib37","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.04.028_bib38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","article-title":"Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy","volume":"92","author":"Arevalo","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.028_bib39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1542\/peds.2012-2996","article-title":"Screening examination of prematurity infants for retinopathy of prematurity","volume":"131","author":"AAP","year":"2013","journal-title":"Pediatrics"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016302056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016302056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T11:59:25Z","timestamp":1536667165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642016302056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0161642016302056"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}